The estimated Net Worth of Raymond R Hipp is at least 7.99 百万$ dollars as of 16 November 2020. Mr. Hipp owns over 70,000 units of Neogenomics stock worth over 1,089,508$ and over the last 11 years he sold NEO stock worth over 6,718,495$. In addition, he makes 182,555$ as Independent Director at Neogenomics.
Sign up
Mr. Hipp NEO stock SEC Form 4 insiders trading
Raymond has made over 5 trades of the Neogenomics stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 70,000 units of NEO stock worth 2,959,600$ on 16 November 2020.
The largest trade he's ever made was selling 150,000 units of Neogenomics stock on 7 May 2019 worth over 3,361,500$. On average, Raymond trades about 21,845 units every 106 days since 2014. As of 16 November 2020 he still owns at least 66,800 units of Neogenomics stock.
You can see the complete history of Mr. Hipp stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Raymond Hipp biography
Raymond R. Hipp serves as Independent Director of the Company. Mr. Hipp has served as a director since February 2011. Mr. Hipp is a retired senior executive that has been involved in consulting work over the last few years involving mergers and acquisitions as well as serving on the board of directors for several public companies. From July 1998 until his retirement in June 2002, Mr. Hipp served as Chairman, President and CEO of Alternative Resources Corporation, a provider of information technology outsourcing services. From August 1996 until May 1998, Mr. Hipp was the Chief Executive Officer of ITI Marketing Services, a provider of marketing services. Prior to that, Mr. Hipp held senior executive positions with several other firms. Mr. Hipp has a B.S. from Southeast Missouri State University. Mr. Hipp served on the board of directors and on the audit committee of Gardner Denver, Inc. (NYSE: GDI), an industrial manufacturing company, for over 14 years.
What is the salary of Raymond Hipp?
As the Independent Director of Neogenomics, the total compensation of Raymond Hipp at Neogenomics is 182,555$. There are 11 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of 3,648,730$.
How old is Raymond Hipp?
Raymond Hipp is 77, he's been the Independent Director of Neogenomics since 2011. There are no older and 26 younger executives at Neogenomics.
What's Raymond Hipp's mailing address?
Raymond's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, 33913.
Insiders trading at Neogenomics
Over the last 12 years, insiders at Neogenomics have traded over 310,374,253$ worth of Neogenomics stock and bought 167,456 units worth 1,699,153$ . The most active insiders traders include Electric Coge Medical Syste...、Oort Douglas M Van、Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of 2,654,175$. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth 16,692$.
What does Neogenomics do?
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
What does Neogenomics's logo look like?
Complete history of Mr. Hipp stock trades at Neogenomics
Neogenomics executives and stock owners
Neogenomics executives and other stock owners filed with the SEC include:
-
Douglas VanOort,
Chairman of the Board, Chief Executive Officer -
Robert Shovlin,
President - Clinical Services Division -
Lawrence Weiss,
Chief Medical Officer -
George Cardoza,
President - Pharma Services Division -
William Bonello,
President, Informatics and Director of Investor Relations -
Douglas M. Brown,
Chief Strategy & Corp. Devel. Officer -
Kathryn McKenzie,
Chief Financial Officer -
Steven Ross,
Chief Information Officer -
Steven Jones,
Director -
Alison Hannah,
Independent Director -
Lynn Tetrault,
Lead Independent Director -
Raymond Hipp,
Independent Director -
Bruce Crowther,
Independent Director -
Kevin Johnson,
Independent Director -
Stephen Kanovsky,
Independent Director -
Michael Kelly,
Independent Director -
Rachel Stahler,
Director -
Douglas Brown,
Chief Strategy and Corporate Development Officer -
Denise Pedulla,
General Counsel, Corporate Secretary -
Jennifer Balliet,
Vice President, Chief Culture Officer -
Stephanie Bywater,
Chief Compliance Officer -
Cynthia Dieter,
Chief Accounting Officer, Controller -
Dr. Steven G. Brodie FACMG, Ph.D.,
Sr. VP of Laboratory Operations -
George A. Cardoza,
Pres & COO of Lab Operations -
Marcus B. Silva J.D., M.B.A.,
Chief Marketing Officer -
Halley E. Gilbert Esq., J.D.,
Chief Legal Officer -
Charlie Eidson,
Director of Investor Relations and Corp. Devel. -
John Mooney,
Chief Technology Officer -
Cynthia J. Dieter,
Chief Accounting Officer & Controller -
Mark W. Mallon,
CEO & Director -
William J Robison,
Director -
Maher Albitar,
Chief Medical Officer -
Sharon Virag,
Chief Financial Officer -
David Sholehvar,
President, Clinical Services -
Neil Gunn,
Director -
Elizabeth Floegel,
Director -
Anthony P. Zook,
Director -
Christopher M Smith,
Chief Executive Officer -
Mark Alan Machulcz,
Vice President of Operations -
Michael T Dent,
Director -
Steven G. Brodie,
Chief Scientific Officer -
Steven Caspen Select Health...,
Executive VP of FinanceExecutive VP of Finance -
Robert H. Horel,
Vice President andGM PathLogic -
Robert P Gasparini,
Chief Science Officer -
Halley E Gilbert,
Chief Legal Officer -
Gina M Wallar,
President, Pharma Services -
Mark Mallon,
Chief Executive Officer -
Clive Morris,
President of Inivata -
Oort Douglas M Van,
Director -
David Daly,
Director -
Vishal Sikri,
President Advanced Diagnostics -
David Brian Perez,
Director -
Jeffrey Scott Sherman,
Chief Financial Officer -
Shashikant Kulkarni,
Chief Scientific Officer -
Alicia C Olivo,
General Counsel -
Melody Harris,
Chf Ops Off, Pres, Informatics -
Greg D Aunan,
Chief Accounting Officer -
Warren Stone,
Chief Commerical Officer